Pharmaceutical tablet
Latest Pfizer Inc. Patents:
- Dosing Regime For Treatment of Chronic Hand Eczema
- Crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one
- Combinations for treatment of NASH/NAFLD and related diseases
- Amorphous Form of (S)-2-(5-((3-Ethoxypyridin-2-YL)Oxy)Pyridin-3-YL)-N-(Tetrahydrofuran-3-YL)Pyrimidine-5-Carboxamide
- Glycoconjugation process
Description
FIG. 1 is a front elevational view of a pharmaceutical tablet of my new design;
FIG. 2 is a top plan view thereof;
FIG. 3 is a bottom plan view thereof;
FIG. 4 is a side elevation view thereof; and
FIG. 5 is a back elevation view of the pharmaceutical tablet shown in FIGS. 1-4.
Referenced Cited
U.S. Patent Documents
D144978 | June 1946 | Owen |
D190729 | June 1961 | Carter |
D229175 | November 1973 | Libertone et al. |
Patent History
Patent number: D263172
Type: Grant
Filed: Sep 18, 1979
Date of Patent: Feb 23, 1982
Assignee: Pfizer Inc. (New York, NY)
Inventor: Kenneth J. Payne (Greenwich, CT)
Primary Examiner: Veronica O'Keefe
Law Firm: Connolly and Hutz
Application Number: 6/76,589
Type: Grant
Filed: Sep 18, 1979
Date of Patent: Feb 23, 1982
Assignee: Pfizer Inc. (New York, NY)
Inventor: Kenneth J. Payne (Greenwich, CT)
Primary Examiner: Veronica O'Keefe
Law Firm: Connolly and Hutz
Application Number: 6/76,589
Classifications
Current U.S. Class:
D28/2;
D28/1;
D 1/12;
Individual Panel Mount Type (13) (D18/29);
424/14;
424/15
International Classification: D2801;
International Classification: D2801;